The price of Danaher Corp. (NYSE:DHR) shares last traded on Wall Street fell -2.13% to $192.65.
Based on available information, 27 analysts follow Danaher Corp. (NYSE:DHR). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $306.00 and a low of $200.00, we find $239.00. Given the previous closing price of $196.84, this indicates a potential upside of 21.42 percent. DHR stock price is now -12.61% away from the 50-day moving average and -12.33% away from the 200-day moving average. The market capitalization of the company currently stands at $142.24B.
Among analysts, 6 rate the stock a hold while 16 rate it a buy. Brokers who have rated the stock have averaged $237.51 as their price target over the next twelve months.
With the price target of $270, Raymond James recently initiated with Outperform rating for Danaher Corp. (NYSE: DHR).
In other news, Gutierrez-Ramos Jose-Carlos, SVP, Chief Science Officer sold 590 shares of the company’s stock on Aug 21. The stock was sold for $147,819 at an average price of $250.54. Upon completion of the transaction, the SVP, Chief Science Officer now directly owns 6,939 shares in the company, valued at $1.34 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jul 28, SVP – Corporate Development Raskas Daniel sold 11,213 shares of the business’s stock. A total of $2,922,652 was realized by selling the stock at an average price of $260.65. This leaves the insider owning 38,288 shares of the company worth $7.38 million. Insiders disposed of 161,101 shares of company stock worth roughly $31.04 million over the past 1 year. A total of 8.81% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in DHR stock. A new stake in Danaher Corp. shares was purchased by VIKING GLOBAL INVESTORS LP during the first quarter worth $820,065,000. HARRIS ASSOCIATES L P invested $447,168,000 in shares of DHR during the first quarter. In the first quarter, COATUE MANAGEMENT LLC acquired a new stake in Danaher Corp. valued at approximately $126,092,000. MERITAGE GROUP LP acquired a new stake in DHR for approximately $93,764,000. UNISUPER MANAGEMENT PTY LTD purchased a new stake in DHR valued at around $63,725,000 in the second quarter. In total, there are 2,837 active investors with 79.55% ownership of the company’s stock.
A candlestick chart of Danaher Corp. (NYSE: DHR) showed a price of $192.83 on Wednesday morning. During the past 12 months, Danaher Corp. has had a low of $192.43 and a high of $249.55. As of last week, the company has a debt-to-equity ratio of 0.41, a current ratio of 2.08, and a quick ratio of 1.70. The fifty day moving average price for DHR is $219.79 and a two-hundred day moving average price translates $219.60 for the stock.
The latest earnings results from Danaher Corp. (NYSE: DHR) was released for Sep, 2023. According to the Diagnostics & Research Company, earnings per share came in at $2.05, beating analysts’ expectations of $2.01 by 0.04. This compares to $2.13 EPS in the same period last year. The net profit margin was 20.74% and return on equity was 12.94% for DHR. The company reported revenue of $6.87 billion for the quarter, compared to $7.66 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -10.31 percent. For the current quarter, analysts expect DHR to generate $6.26B in revenue.
Moreover, the firm recently paid out its quarterly dividend on 10/27/2023. Investors who held shares on 10/12/2023 were paid a $0.27 dividend. On an annualized basis, this represents a $0.94 dividend and a 0.49% percent yield. There was an ex-dividend date of 10/11/2023 for this dividend. In terms of dividend payout ratio, DHR is presently at 10.35%.
Danaher Corp.(DHR) Company Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology, molecular, acute care, and pathology diagnostics products. This segment offers clinical instruments, reagents, consumables, software, and services for hospitals, physicians’ offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, municipal, industrial, and natural resource applications. It also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. The company was founded in 1969 and is headquartered in Washington, the District of Columbia.
